Ignite Creation Date:
2024-05-06 @ 12:21 AM
Last Modification Date:
2024-10-26 @ 10:48 AM
Study NCT ID:
NCT01551056
Status:
COMPLETED
Last Update Posted:
2017-11-07
First Post:
2012-03-08
Brief Title:
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 024 Compared to Vehicle in the Conjunctival Allergen Challenge CAC
Sponsor:
Aciex Therapeutics Inc
Organization:
Aciex Therapeutics Inc
Study Overview
Official Title:
A Multi-Center Double-Masked Randomized Vehicle-Controlled Evaluation of the Onset and Duration of Action of Cetirizine 024 Ophthalmic Solution Formula AFH-002 Compared to Vehicle Formula AFH-001 in the Conjunctival Allergen Challenge CAC Model of Acute Allergic Conjunctivitis
Status:
COMPLETED
Status Verified Date:
2017-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the onset and duration of action of AC-170 024 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge CAC model
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None